merged_alzheimers-treatment-kisunla-donanemab.txt
<question_number>1</question_number>
<answer>modest benefit and significant safety risks</answer>
<question_number>2</question_number>
<answer>discourage patients from participating in trials for better treatments</answer>
<question_number>3</question_number>
<answer>no correlation</answer>
<question_number>4</question_number>
<answer>negatively impact the perception of Kisunla's safety</answer>
<question_number>5</question_number>
<answer>patients can stop Kisunla after plaques are cleared</answer>
<question_number>6</question_number>
<answer>discourage patients from participating in trials for better treatments</answer>
<question_number>7</question_number>
<answer>less frequent infusions and possibility to stop treatment</answer>
<question_number>8</question_number>
<answer>amyloid</answer>
<question_number>9</question_number>
<answer>Dr. Michael Greicius</answer>
<question_number>10</question_number>
<answer>intermediate tau levels leading to slower decline</answer>